Search results
Showing 1 to 15 of 82 results for colitis
This guideline covers using colonoscopy to check for signs of bowel cancer in people aged 18 and over with ulcerative colitis or Crohn’s disease (types of inflammatory bowel disease) or adenomas (also known as polyps). It aims to prevent cancer and prolong life by offering advice on identifying early bowel cancer in adults most at risk.
This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.
This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, including advice about symptoms and when to seek help.
Coeliac disease: recognition, assessment and management (NG20)
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making
Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making
In development [GID-TA11352] Expected publication date: TBC
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults.
PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis (MIB313)
NICE has developed a medtech innovation briefing (MIB) on PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis .
This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.
Clostridioides difficile infection: antimicrobial prescribing (NG199)
This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.
Faecal microbiota transplant for recurrent Clostridium difficile infection (IPG485)
Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridium difficile infection. This involves introducing enteric bacteria from the faeces of healthy donors to restore a healthy balance of bacteria in the gut.
PredictSURE IBD and IBDX to guide treatment of Crohn's disease (DG45)
Evidence-based recommendations on PredictSURE IBD and IBDX for guiding treatment of Crohn’s disease
Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated